In contrast to other fusion transcripts41–43, the DNAJB1-PRKACA fusion generates a defined and unique protein sequence that allows an off-the-shelf application of DNAJB1-PRKACA-derived neoepitopes in cancer immunotherapy. This evidence concerns the gene PRKACA and cancer.